Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Atlantic Coastal Acquisition Ii's Competitiveness

Name: Atlantic Coastal Acquisition Ii Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Atlantic Coastal Acquisition Ii (ACAB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ACAB/competitors                    

                        https://api.csimarket.com/api/v1/companies/ACAB/relationships                    

                        https://api.csimarket.com/api/v1/companies/ACAB/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Atlantic Coastal Acquisition Ii's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Atlantic Coastal Acquisition Corp Ii	-	-	-	No
High-Confidence Competitors (8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

ACAB Stock Performance relative to its Competitors

ACAB Competitors (weighted) Percent change over the selected range

Atlantic Coastal Acquisition Ii's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(6 of 7)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Atlantic Coastal Acquisition Corp Ii	-43.80 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (7)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Atlantic Coastal Acquisition Ii's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

ACAB Stock Performance relative to High-Confidence Competitors

ACAB High-Confidence Competitors (equal-weighted, 9) Percent change over the selected range

Atlantic Coastal Acquisition Ii's Comment on Competition and Industry Peers

The company operates in the biotechnology and biopharmaceutical industries, with a focus on immuno-oncology and ophthalmology. Its competitors include large biopharmaceutical firms, specialty biotechnology companies, academic research departments, and public and private research institutions developing potentially competitive products and technologies. In immune-based cancer treatments such as T-cell engager, CAR T, and TCR therapies, competitors include Amgen, Bristol-Myers Squibb Company, Janux, J&J, Genentech, Inc. (a member of the Roche Group), Vir Bio, and Xencor. In ophthalmology-related treatments, competitors include Allergan plc, Genentech/Roche, Novartis International AG, and Regeneron Pharmaceuticals, Inc. Many of these competitors possess substantially greater financial, technical, and human resources, which may enhance their ability to obtain regulatory approvals and achieve market acceptance. Additionally, merger and acquisition activity in the industry may concentrate resources among fewer competitors.

Competitor data is not yet available for Atlantic Coastal Acquisition Ii.

Atlantic Coastal Acquisition Ii's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Allergan plc	Named by the company	85%	2022 to 2026	3
Novartis International AG	Named by the company	85%	2022 to 2026	3
Genentech, Inc.	Named by the company	85%	2022 to 2026	3
Xencor	Named by the company	85%	2022 to 2026	3
Amgen	Named by the company	85%	2022 to 2026	3
Regeneron Pharmaceuticals, Inc.	Named by the company	85%	2022 to 2026	3
Janux	Named by the company	85%	2022 to 2026	3
Bristol-Myers Squibb Company	Named by the company	85%	2022 to 2026	3
Vir Bio	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Atlantic Coastal Acquisition Ii's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.